corporate overview


investors & media


investors & media

Investor Relations Home

Rigel currently has the following product candidates in development: fostamatinib, an oral SYK inhibitor, which is in Phase 3 clinical trials for ITP and is expected to enter a Phase 2 clinical trial for IgA Nephropathy in the second half of 2014; R348, an ophthalmic JAK/SYK inhibitor, in a Phase 2 clinical trial for dry eye in GvHD; and two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

Stock Quote
RIGL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.04 (1.56%)
Data as of 08/29/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
2014 Q2 10-Q  - PDF 
2014 Q2 10-Q
2013 Annual Report - PDF 
2013 Annual Report
Financial Tear Sheet - PDF 
Financial Tear Sheet
Recent NewsMore >>
08/13/14R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study
Rigel Reiterates Clinical Focus on Fostamatinib for ITP and IgA Nephropathy SOUTH SAN FRANCISCO, Calif., Aug. 13, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease.  The endpoints were measured by changes in corneal fluorescein staining, conjunctival staining, tear production and dry eye sym... 
Printer Friendly Version
08/05/14Rigel Announces Second Quarter 2014 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 5, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2014. For the second quarter of 2014, Rigel reported a net loss of $25.4 million, or $0.29 per share, compared to a net loss of $22.8 million, or $0.26 per share, in the same period of 2013. Weighted average shares outstanding for the second quarters of 2014 and 2013 were 87.5 million and 87.1 million, respect... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Most Viewed Links
Updated 08/29/14
1.R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study
2.Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
3.Rigel Announces Second Quarter 2014 Financial Results
4.Rigel Announces Publication of R118 AMPK Activator Research
5.Current Financial Reports
* Data collected 08/21/14 - 08/28/14
Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
© 2014 Rigel  |  privacy  |  disclaimer  | Follow Us On:contact us | site map |  search    Search